Research ExplorerPublicationsResponse-adapted lenalidomide maintenance in newly diagnosed...

Response-adapted lenalidomide maintenance in newly diagnosed myeloma

Standard

Response-adapted lenalidomide maintenance in newly diagnosed myeloma : results from the phase III GMMG-MM5 trial. / Goldschmidt, Hartmut; Mai, Elias K; Dürig, Jan; Scheid, Christof; Weisel, Katja C; Kunz, Christina; Bertsch, Uta; Hielscher, Thomas; Merz, Maximilian; Munder, Markus; Lindemann, Hans-Walter; Hügle-Dörr, Barbara; Tichy, Diana; Giesen, Nicola; Hose, Dirk; Seckinger, Anja; Huhn, Stefanie; Luntz, Steffen; Jauch, Anna; Elmaagacli, Ahmet; Rabold, Bernhard; Fuhrmann, Stephan; Brossart, Peter; Goerner, Martin; Bernhard, Helga; Hoffmann, Martin; Hillengass, Jens; Raab, Marc S; Blau, Igor W; Hänel, Mathias; Salwender, Hans J; German-speaking Myeloma Multicenter Group (GMMG).

In: LEUKEMIA, Vol. 34, No. 7, 07.2020, p. 1853-1865.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Goldschmidt, H, Mai, EK, Dürig, J, Scheid, C, Weisel, KC, Kunz, C, Bertsch, U, Hielscher, T, Merz, M, Munder, M, Lindemann, H-W, Hügle-Dörr, B, Tichy, D, Giesen, N, Hose, D, Seckinger, A, Huhn, S, Luntz, S, Jauch, A, Elmaagacli, A, Rabold, B, Fuhrmann, S, Brossart, P, Goerner, M, Bernhard, H, Hoffmann, M, Hillengass, J, Raab, MS, Blau, IW, Hänel, M, Salwender, HJ & German-speaking Myeloma Multicenter Group (GMMG) 2020, 'Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial', LEUKEMIA, vol. 34, no. 7, pp. 1853-1865. https://doi.org/10.1038/s41375-020-0724-1

APA

Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., Lindemann, H-W., Hügle-Dörr, B., Tichy, D., Giesen, N., Hose, D., Seckinger, A., Huhn, S., Luntz, S., Jauch, A., ... German-speaking Myeloma Multicenter Group (GMMG) (2020). Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. LEUKEMIA, 34(7), 1853-1865. https://doi.org/10.1038/s41375-020-0724-1

Vancouver

Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. LEUKEMIA. 2020 Jul;34(7):1853-1865. https://doi.org/10.1038/s41375-020-0724-1

Bibtex

@article{1edac6f1e38a41029d632c7887d9d9bb,
title = "Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial",
abstract = "The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n = 502): arms A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR (n = 126), A2:VCD + LEN-2Y (n = 126), B2:VCD + LEN-CR (n = 125). In the LEN-CR group (B1 + B2), n = 88/17.5% patients did not start or discontinued LEN MT due to CR. There was no PFS (p = 0.60, primary endpoint) nor overall survival (OS) (p = 0.15) difference between the four study arms. On pooled LEN MT strategies, OS (hazard ratio, hazard ratio [HR] = 1.42, p = 0.03) but not PFS (HR = 1.15, p = 0.20) was shorter in LEN-CR (B1 + B2) vs. LEN-2Y (A1 + A2) groups. PFS was shortened on landmark analyses from the start of LEN MT in patients being in CR in the LEN-CR group (LEN-CR vs. LEN-2Y, HR = 1.84, p = 0.02). OS from first progression was shortened in the LEN-CR vs. LEN-2Y group (HR = 1.60, p = 0.01). LEN MT should be applied beyond CR for at least 2 years.",
author = "Hartmut Goldschmidt and Mai, {Elias K} and Jan D{\"u}rig and Christof Scheid and Weisel, {Katja C} and Christina Kunz and Uta Bertsch and Thomas Hielscher and Maximilian Merz and Markus Munder and Hans-Walter Lindemann and Barbara H{\"u}gle-D{\"o}rr and Diana Tichy and Nicola Giesen and Dirk Hose and Anja Seckinger and Stefanie Huhn and Steffen Luntz and Anna Jauch and Ahmet Elmaagacli and Bernhard Rabold and Stephan Fuhrmann and Peter Brossart and Martin Goerner and Helga Bernhard and Martin Hoffmann and Jens Hillengass and Raab, {Marc S} and Blau, {Igor W} and Mathias H{\"a}nel and Salwender, {Hans J} and {German-speaking Myeloma Multicenter Group (GMMG)}",
year = "2020",
month = jul,
doi = "10.1038/s41375-020-0724-1",
language = "English",
volume = "34",
pages = "1853--1865",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Response-adapted lenalidomide maintenance in newly diagnosed myeloma

T2 - results from the phase III GMMG-MM5 trial

AU - Goldschmidt, Hartmut

AU - Mai, Elias K

AU - Dürig, Jan

AU - Scheid, Christof

AU - Weisel, Katja C

AU - Kunz, Christina

AU - Bertsch, Uta

AU - Hielscher, Thomas

AU - Merz, Maximilian

AU - Munder, Markus

AU - Lindemann, Hans-Walter

AU - Hügle-Dörr, Barbara

AU - Tichy, Diana

AU - Giesen, Nicola

AU - Hose, Dirk

AU - Seckinger, Anja

AU - Huhn, Stefanie

AU - Luntz, Steffen

AU - Jauch, Anna

AU - Elmaagacli, Ahmet

AU - Rabold, Bernhard

AU - Fuhrmann, Stephan

AU - Brossart, Peter

AU - Goerner, Martin

AU - Bernhard, Helga

AU - Hoffmann, Martin

AU - Hillengass, Jens

AU - Raab, Marc S

AU - Blau, Igor W

AU - Hänel, Mathias

AU - Salwender, Hans J

AU - German-speaking Myeloma Multicenter Group (GMMG)

PY - 2020/7

Y1 - 2020/7

N2 - The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n = 502): arms A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR (n = 126), A2:VCD + LEN-2Y (n = 126), B2:VCD + LEN-CR (n = 125). In the LEN-CR group (B1 + B2), n = 88/17.5% patients did not start or discontinued LEN MT due to CR. There was no PFS (p = 0.60, primary endpoint) nor overall survival (OS) (p = 0.15) difference between the four study arms. On pooled LEN MT strategies, OS (hazard ratio, hazard ratio [HR] = 1.42, p = 0.03) but not PFS (HR = 1.15, p = 0.20) was shorter in LEN-CR (B1 + B2) vs. LEN-2Y (A1 + A2) groups. PFS was shortened on landmark analyses from the start of LEN MT in patients being in CR in the LEN-CR group (LEN-CR vs. LEN-2Y, HR = 1.84, p = 0.02). OS from first progression was shortened in the LEN-CR vs. LEN-2Y group (HR = 1.60, p = 0.01). LEN MT should be applied beyond CR for at least 2 years.

AB - The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n = 502): arms A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR (n = 126), A2:VCD + LEN-2Y (n = 126), B2:VCD + LEN-CR (n = 125). In the LEN-CR group (B1 + B2), n = 88/17.5% patients did not start or discontinued LEN MT due to CR. There was no PFS (p = 0.60, primary endpoint) nor overall survival (OS) (p = 0.15) difference between the four study arms. On pooled LEN MT strategies, OS (hazard ratio, hazard ratio [HR] = 1.42, p = 0.03) but not PFS (HR = 1.15, p = 0.20) was shorter in LEN-CR (B1 + B2) vs. LEN-2Y (A1 + A2) groups. PFS was shortened on landmark analyses from the start of LEN MT in patients being in CR in the LEN-CR group (LEN-CR vs. LEN-2Y, HR = 1.84, p = 0.02). OS from first progression was shortened in the LEN-CR vs. LEN-2Y group (HR = 1.60, p = 0.01). LEN MT should be applied beyond CR for at least 2 years.

U2 - 10.1038/s41375-020-0724-1

DO - 10.1038/s41375-020-0724-1

M3 - SCORING: Journal article

C2 - 32034285

VL - 34

SP - 1853

EP - 1865

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 7

ER -